- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951281
Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening
Evaluation of the Clinical Performance of Lumetry for paCO2 Assessment and COPD Screening
The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).
lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.
Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.
In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.
The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ruth Masih, MSc Biotechnology
- Número de teléfono: +4366488262391
- Correo electrónico: ruth.masih@lumetry.at
Copia de seguridad de contactos de estudio
- Nombre: Nejla Hidic, BSc Biomedical Engineering
- Número de teléfono: +4366488262391
- Correo electrónico: nejla.hidic@lumetry.at
Ubicaciones de estudio
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, A-1210
- Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine
-
Contacto:
- Arschang Valipour, Prim. Priv. -Doz. Dr.
- Correo electrónico: arschang.valipour@gesundheitsverbund.at
-
Contacto:
- Theresa Klemm, Medical Doctor
- Correo electrónico: theresa.klemm@gesundheitsverbund.at
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent
- Age between 18 and 90 years
- Diagnosed chronic obstructive pulmonary disease (COPD), stages GOLD I to IV, or no known lung function pathologies
- Able to sit upright for the duration of the procedure without exhaustion
- Women of childbearing potential: not breastfeeding and either a negative pregnancy test prior to the start of the investigation or use of a reliable method of contraception (intrauterine device or oral contraceptive pill) throughout the investigation. Women of childbearing potential are defined as women who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal (at least 12 months of amenorrhea in a woman over the age of 50 in the absence of other biological or physiological causes).
Exclusion Criteria:
- Considered by the investigator to be inappropriate for inclusion or unlikely to comply with the requirements of the study
- Lung disease other than COPD (e.g., asthma); participants with asthma-COPD overlap may be included
- Previously documented chronic heart failure with an ejection fraction below 40%
- Mental or physical inability to comply with time schedules and study procedures
- Current participation in a clinical study that may affect breathing behaviour (medicinal product or medical device), or participation within 30 days prior to screening
- Prior participation in this clinical investigation
- Possible or confirmed pregnancy, or breastfeeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Participants With and Without COPD
Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring. |
Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate. Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only. Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD. Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
Periodo de tiempo: Day 1 (single study visit)
|
In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value. |
Day 1 (single study visit)
|
|
Sensitivity of the lumetry COPD Screening Result
Periodo de tiempo: Day 1 (single study visit)
|
Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result. |
Day 1 (single study visit)
|
|
Specificity of the lumetry COPD Screening Result
Periodo de tiempo: Day 1 (single study visit)
|
Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result. |
Day 1 (single study visit)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
Periodo de tiempo: Day 1 (single study visit)
|
In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
|
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
Periodo de tiempo: Day 1 (single study visit)
|
In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard). |
Day 1 (single study visit)
|
|
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)
Periodo de tiempo: Day 1 (single study visit)
|
In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies
Periodo de tiempo: Day 1 (single study visit)
|
Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit. |
Day 1 (single study visit)
|
|
Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm
Periodo de tiempo: Day 1 (single study visit)
|
Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis. |
Day 1 (single study visit)
|
|
Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm
Periodo de tiempo: Day 1 (single study visit)
|
Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis. |
Day 1 (single study visit)
|
|
Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2
Periodo de tiempo: Day 1 (single study visit)
|
Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg). |
Day 1 (single study visit)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Arschang Valipour, Prim. Priv. -Doz. Dr., Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine
Publicaciones y enlaces útiles
Publicaciones Generales
- Klemm et al. Predicting arterial pCO2 using capnographic recordings - A pilot study using a novel breath analysis device. Eur Respir J. 2025; 66(Suppl 69): PA2529. doi:10.1183/13993003.congress-2025.PA2529
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Enfermedades Pulmonares Obstructivas
- Signos y Síntomas Respiratorios
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Enfermedad Pulmonar Obstructiva Crónica
- Hipercapnia
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Técnicas de diagnóstico, sistema respiratorio
- Técnicas de diagnóstico, cardiovascular
- Pruebas de funciones cardíacas
- Pruebas de funciones respiratorias
- Análisis de químicos de sangre
- Pruebas de química clínica
- Análisis de Gases Sanguíneos
- Oximetría
- Monitorización Transcutánea de Gases Sanguíneos
Otros números de identificación del estudio
- lumetry_03
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .